CONFERENCE SPEAKERS

Speakers
Richard Dennis
Richard Dennis
Chief Commercial Officer,
Proteome Sciences

Richard is the CCO at Proteome Sciences and has over 30 years’ experience working in the proteomics and biotechnology sectors. Since joining Proteome Sciences in 2017 he has focused on leading the Company’s marketing and commercialisation strategy to offer clients a flexible, high quality service in our CRO business.


Takami Sato
Takami Sato
Professor of Medical Oncology Research Director,
Thomas Jefferson University


Roger Waltzman
Roger Waltzman
Chief Medical Officer,
Indaptus Therapeutics


Leena Gandhi
Leena Gandhi
Chief Medical Officer,
NextPoint Therapeutics


Aurélie Auguste
Aurélie Auguste
Director, Translational Data Analysis,
Veracyte


Samir Hanash
Samir Hanash
Director, McCombs Institute for Cancer Detection and Treatment,
MD Anderson Cancer Center


Joseph Ferrara
Joseph Ferrara
Chief Strategy Officer,
Veranex


Ravinder Singh
Ravinder Singh
Professor of Laboratory Medicine and Pathology,
Mayo Clinic


Russell Weiner
Russell Weiner
Head Oncology and Cell Therapy Clinical Biomarker Sciences,
Takeda


Ginette Serrero
Ginette Serrero
CEO, Precision Antibody,
A&G Pharmaceutical, Inc. | Precision Antibody

Dr. Ginette Serrero is Chief Executive Officer of Precision Antibody, a custom antibody development company, expert in the design, development, characterization and production of monoclonal antibodies for the treatment and diagnosis of human diseases. She draws on biotech management and research expertise in Oncology and biomarker discovery to guide the company's strategy in both the service division and R&D department for the development of biological targeted therapies with companion tissue and serum diagnostics for breast cancer. Her laboratory discovered Progranulin (GP88) as a marker of recurrence, drug resistance and tumor aggressiveness for several cancers including breast and lung cancer. This led to the development of two companion diagnostics that have been clinically validated for disease prognosis and monitoring of breast and lung cancer patients. She is a trained Biochemist with expertise in target discovery, Pharmaceutical Sciences and Oncology.  She is Adjunct Professor at the University of Maryland Greenebaum Comprehensive Cancer Center.

She is inventor on several worldwide patents for targets in Oncology and authored 100 peer-reviewed scientific publications and reviews.


Joanne Lim
Joanne Lim
Associate Director, Immunology,
Orum Therapeutics


Anu Santhanagopal
Anu Santhanagopal
Head US Oncology Medical Affairs Strategy,
Boehringer Ingelheim


Ariel Lefkovith
Ariel Lefkovith
Manager, Biomarker Operations,
Repare Therapeutics


Vaibhav Saini
Vaibhav Saini
Senior Commercialization Manager,
Northeastern University


Yi-Ya Fang
Yi-Ya Fang
Senior advisor,
Eli Lilly and Company


Lindsay Darling
Lindsay Darling
Director, Companion Diagnostics Portfolio Management & Operations,
Regeneron


Alexander Kuklin
Alexander Kuklin
Vice President CDx and BioPharma Partnerships,
Predicine


Alok Pandey
Alok Pandey
Vice President, Biomarker & Translational Science,
PBL Assay Science


Allen Feng
Allen Feng
Founder and Chief Scientific Officer,
HebeCell Corporation


Aaron Goldman
Aaron Goldman
Faculty and Instructor in Medicine,
Harvard Medical School


Althea Lang
Althea Lang
Scientific Project Manager, Translational Science,
Foundation for the National Institutes of Health


Chakravarthy Garlapati
Chakravarthy Garlapati
Senior Scientist, (Molecular and Cell Pharmacology),
Alkermes


Raluca Budiu-Predoiu
Raluca Budiu-Predoiu
Director, Companion Diagnostics Strategy Lead, ,
Abbvie


Rakesh Dixit
Rakesh Dixit
CEO,
Bionavigen

Rakesh Dixit is a President & CEO, BIONAVIGEN, LLC, a biopharmaceutical virtual drug development company specializing in advising and consulting for all aspects of drug development, including discovery, preclinical development, CMC, translational sciences, clinical development and regulatory filing. Accomplished executive, inventor, and scientist with over 30 years of success with top biotechnology and pharmaceutical companies, including Merck, Johnson & Johnson, Medimmune, AstraZeneca.


Siamak Tabrizi
Siamak Tabrizi
Senior Scientist,
Immunitas Therapeutics


Howard Kaufman
Howard Kaufman
President and CEO, Lecturer,
Ankyra Therapeutics, Harvard Medical School


Allison Drain
Allison Drain
Preclinical Development,
Affini-T Therapeutics


Collin Hudzik
Collin Hudzik
Scientist,
EpigenDx

Collin is a Scientist at EpigenDx in product and business development.  He graduated from the Pennsylvania State University in 2023 with his Ph.D. in Plant Biology with a focus in genetics, specifically in the accumulation and biogenesis of microRNAs and secondary small interfering RNAs. 


Bhaskarjyoti Sarmah
Bhaskarjyoti Sarmah
Associate Scientific Director, Clinical Biomarkers,
Moderna


David Yu
David Yu
Director, Precision Medicine and Translational Medicine,
Bristol Myers Squibb


Wenting Wang
Wenting Wang
Oncology Biomarker Statistics Team Lead,
Sanofi


Amanda Acerbi
Amanda Acerbi
Precision Medicine Global Director,
Janssen


Lanye Huang
Lanye Huang
Business Development Executive/ Senior BD Manager,
SanyouBio


Mario Flores
Mario Flores
Assistant Professor, Department of Biomedical Engineering,
The University of Texas at San Antonio


Zheng Feng
Zheng Feng
Head, Molecular Biomarkers & Genomics,
EMD Serono


Melis McHenry
Melis McHenry
Associate Director, Precision Medicine CDx,
Regeneron


Shriya Joshi
Shriya Joshi
Scientist, small molecule drug discovery,
Bristol Myers Squibb


Frank Borriello
Frank Borriello
Founder and CEO,
Alloplex Biotherapeutics

Dr. Borriello is Harvard Trained Pathologist having trained at the Brigham and Women’s Hospital in the division of immunology where he worked with Arlene Sharpe and Gordon Freeman on the B7-CD28 pathway; co-authoring several pivotal papers in the costimulatory field. He obtained his MD, PhD degrees at the Albert Einstein College of Medicine in NYC where he also worked with Dr. Stanley Nathenson on structure-function relationships in the MHC Class I surface antigens. Dr. Borriello transitioned from academic life to the pharmaceutical/financial sectors in 1999 and has been a pharma business development professional since 2006.  In 2016, he was the head of search and evaluation at Baxalta across multiple therapeutic areas until the Shire acquisition, after which he left to found Alloplex Biotherapeutics in pursuit of an idea of his own invention in tumor immunology.  He currently lives with his wife and daughter in the Boston area.


Tyler Nielsen
Tyler Nielsen
Sr Scientist,
Oncocyte Corporation


Christopher Garris
Christopher Garris
Assistant Professor of Pathology,
Massachusetts General Hospital, Harvard Medical School

Christopher Garris is an Assistant professor at the Massachusetts General Hospital. By monitoring key hallmarks of anti-tumor immune function, we have developed novel platforms for combination immunotherapy selection in the re-programming of myeloid cells towards anti-tumor phenotypes.